sch 51048 has been researched along with Aspergillosis in 2 studies
*Aspergillosis: Infections with fungi of the genus ASPERGILLUS. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, F; Cacciapuoti, A; Ganguly, AK; Girijavallabhan, VM; Hare, RS; Jao, E; Liu, YT; Loebenberg, D; Lovey, RG; Menzel, F; Moss, E; Nomeir, A; Patel, NM; Pike, R; Pinto, P; Saksena, AK; Wang, H | 1 |
| Allendoerfer, R; Graybill, JR; Loebenberg, D; Rinaldi, MG | 1 |
2 other study(ies) available for sch 51048 and Aspergillosis
| Article | Year |
|---|---|
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].
Topics: Alcohols; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Haplorhini; Humans; Immunosuppressive Agents; Mice; Models, Chemical; Time Factors; Triazoles | 2006 |
Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Evaluation; Female; Itraconazole; Lung Diseases, Fungal; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Survival Rate; Triazoles | 1995 |